Phase 3 Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 to 70 years who have been diagnosed with metastatic breast cancer, confirmed by tissue testing or imaging
- People whose cancer has been tested and confirmed as HER2-negative (a specific result on two types of laboratory tests)
- People whose cancer has tested positive for HRD (a marker of DNA repair problems in the tumour, either through a BRCA1/2 gene mutation or a high HRD score)
- People with HR-positive/HER2-negative metastatic breast cancer who have already received hormone-based therapy during the metastatic stage
- People who have received no more than two chemotherapy or similar drug regimens for their metastatic breast cancer
- People whose most recent anti-cancer treatment (6 to 8 cycles) showed clinical benefit — meaning the cancer shrank, disappeared, or stayed stable for at least 24 weeks
- People with a general physical fitness score of 2 or lower on a standard medical scale, and an expected survival of at least 3 months
- People with at least one measurable area of cancer visible on imaging within the 2 weeks before joining, or bone-only spread
- People whose side effects from previous treatments have mostly resolved before joining (with some exceptions such as hair loss)
- People with adequate bone marrow function, shown by blood counts meeting specific minimum levels
- People with liver, kidney, and heart function results that fall within acceptable ranges on standard tests
- People who are able to understand the study process and willing to sign a consent form
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with HR-positive/HER2-negative metastatic breast cancer who have never received hormone-based therapy
- People who have not received any treatment at all for their metastatic breast cancer
- People who have already received more than two chemotherapy regimens for metastatic breast cancer
- People with a known allergy to any ingredient in the study drug
- Women who are pregnant or breastfeeding, or women of childbearing potential who are unwilling to use effective contraception during the study
- People with serious heart conditions that are expected to make chemotherapy unsafe, such as severe irregular heartbeat, unstable chest pain, significant heart valve disease, a recent major heart attack shown on an ECG, or uncontrolled high blood pressure
- People with other medical conditions, infections, or circumstances that the trial doctor considers unsafe or unsuitable for participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jianli Zhao, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phone: 86-20-34070870
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression Free Survival，PFS（Independent Review Committee）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.